Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Zedge And 2 Other Stocks Insiders Are Buying
Although Dow Jones closed higher by around 500 points on Tuesday, there were a few notable insider trades.
TELA Bio: Q4 Earnings Insights
TELA Bio (NASDAQ:TELA) reported its Q4 earnings results on Monday, March 21, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
TELA Bio missed estimated earnings by 7.27%, reporting an EPS of $-0.59 versus an estimate of $-0.55.
TELA Bio Q4 EPS $(0.59) Misses $(0.55) Estimate, Sales $8.37M Beat $7.98M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by 7.27 percent. This is a 9.26 percent decrease over losses of $(0.54) per share from the same
Earnings Scheduled For March 21, 2022
Companies Reporting Before The Bell
• Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
Preview: TELA Bio’s Earnings
TELA Bio (NASDAQ:TELA) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement.
Analysts estimate that TELA Bio will report an earnings per share (EPS) of $-0.55.
TELA Bio Announces U.S. Commercial Launch Of SiteGuard No Rinse Antimicrobial Solution
TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and
TELA Bio Q3 EPS $(0.57) Misses $(0.52) Estimate, Sales $7.70M Beat $7.55M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.52) by 9.62 percent. This is a 7.55 percent decrease over losses of $(0.53) per share from the same
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.